Combination

Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma
Weixiong Yang, Xiangbin Xing, Sai-Ching Jim Yeung, Siyu Wang, Wenfang Chen, Yong Bao, Fang Wang, Shiting Feng, Fang Peng, Xiaoyan Wang, Shuling Chen, Minghui He, Ning Zhang, Honglei Wang, Bo Zeng, Zhenguo Liu, Biniam Kidane, Christopher W Seder, Kazuo Koyanagi, Yaron Shargall, Honghe Luo, Sui Peng, Chao Cheng

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003497; DOI: 10.1136/jitc-2021-003497
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Paolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, Todd M Bauer, Marcello Tucci, Antoine Italiano, Roberto Iacovelli, Wu-Chou Su, Christophe Massard, Mansoor Saleh, Gennaro Daniele, Alastair Greystoke, Martin Gutierrez, Shubham Pant, Ying-Chun Shen, Matteo Perrino, Robin Meng, Giovanni Abbadessa, Helen Lee, Yingwen Dong, Marielle Chiron, Rui Wang, Laure Loumagne, Lucie Lépine, Johann de Bono

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003697; DOI: 10.1136/jitc-2021-003697
Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study
Akie Kimura Yoshikawa, Kensei Yamaguchi, Kei Muro, Atsuo Takashima, Takashi Ichimura, Daisuke Sakai, Shigenori Kadowaki, Keisho Chin, Toshihiro Kudo, Seiichiro Mitani, Shigehisa Kitano, Dung Thai, Marianna Zavodovskaya, JieJane Liu, Narikazu Boku, Taroh Satoh

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003518; DOI: 10.1136/jitc-2021-003518
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
Marc Wehrli, Kathleen Gallagher, Yi-Bin Chen, Mark B Leick, Steven L McAfee, Areej R El-Jawahri, Zachariah DeFilipp, Nora Horick, Paul O'Donnell, Thomas Spitzer, Bimal Dey, Daniella Cook, Michael Trailor, Kevin Lindell, Marcela V Maus, Matthew J Frigault

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003847; DOI: 10.1136/jitc-2021-003847
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
Osama E Rahma, Kevin Tyan, Anita Giobbie-Hurder, Andrew S Brohl, Philippe L Bedard, Daniel J Renouf, Elad Sharon, Howard Streicher, Emma Hathaway, Rachel Cunningham, Michael Manos, Mariano Severgnini, Scott Rodig, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003569; DOI: 10.1136/jitc-2021-003569
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly-Khan Lalani, Caroline Robert, Padmanee Sharma, Solange Peters

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003024; DOI: 10.1136/jitc-2021-003024
Combined inhibition of CXCL12 and PD-1 in MSS colorectal and pancreatic cancer: modulation of the microenvironment and clinical effects
Meggy Suarez-Carmona, Anja Williams, Jutta Schreiber, Nicolas Hohmann, Ulrike Pruefer, Jürgen Krauss, Dirk Jäger, Anna Frömming, Diana Beyer, Dirk Eulberg, Jarf Ulf Jungelius, Matthias Baumann, Aram Mangasarian, Niels Halama

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e002505; DOI: 10.1136/jitc-2021-002505
Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
Chia-Ing Jan, Shi-Wei Huang, Peter Canoll, Jeffrey N Bruce, Yu-Chuan Lin, Chih-Ming Pan, Hsin-Man Lu, Shao-Chih Chiu, Der-Yang Cho

Journal for ImmunoTherapy of Cancer Oct 2021, 9 (10) e003050; DOI: 10.1136/jitc-2021-003050
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Shaoming Zhu, A-Hong Ma, Zheng Zhu, Elio Adib, Ting Rao, Na Li, Kaiyuan Ni, Veera Chandra Sekhar Reddy Chittepu, Rao Prabhala, Juan Garisto Risco, David Kwiatkowski, Kent Mouw, Guru Sonpavde, Fan Cheng, Chong-xian Pan

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e002917; DOI: 10.1136/jitc-2021-002917
DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma
Allison A Fitzgerald, Shangzi Wang, Veena Agarwal, Emily F Marcisak, Annie Zuo, Sandra A Jablonski, Melanie Loth, Elana J Fertig, John MacDougall, Eugene Zhukovsky, Shubhendu Trivedi, Dimple Bhatia, Vince O'Neill, Louis M Weiner

Journal for ImmunoTherapy of Cancer Nov 2021, 9 (11) e002837; DOI: 10.1136/jitc-2021-002837

Main menu

Combination

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Combination

Pages